Trial reportSurgical endoscopy2018
Safety and efficacy of the endoscopic duodenal-jejunal bypass liner prototype in severe or morbidly obese subjects implanted for up to 3 years.
Trial report in Surgical endoscopy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Effects of Bariatric Endoscopy on Non-Alcoholic Fatty Liver Disease: A Comprehensive Systematic Review and Meta-Analysis.Frontiers in endocrinology · 2022Pooled it
- Is duodeno-jejunal bypass liner superior to pylorus preserving bariatric surgery in terms of complications and efficacy?Langenbeck's archives of surgery · 2021Pooled it
- Relevant Weight Reduction and Reversed Metabolic Co-morbidities Can Be Achieved by Duodenojejunal Bypass Liner in Adolescents with Morbid Obesity.Obesity surgery · 2020Trial
- Mechanism of action and selection of endoscopic bariatric therapies for treatment of obesity.Clinical endoscopy · 2024Review
- Sustained weight loss after duodenal-jejunal bypass liner treatment in patients with body mass index below, but not above 35 kg/mClinical obesity · 2023Article
- Endoscopic Bariatric Treatment with Duodenal-Jejunal Bypass Liner Improves Non-invasive Markers of Non-alcoholic Steatohepatitis.Obesity surgery · 2022Article
- Bariatric and Metabolic Endoscopy: A New Paradigm.Clinical and translational gastroenterology · 2021Review
- Various Novel and Emerging Technologies in Endoscopic Bariatric and Metabolic Treatments.Clinical endoscopy · 2021Article
- Clinical follow-up on weight loss, glycemic control, and safety aspects of 24 months of duodenal-jejunal bypass liner implantation.Surgical endoscopy · 2020Observational
- New Anchoring Mechanism and Design of an Endoluminal Duodeno-Jejunal Bypass Liner for Treatment of Obesity: a Pilot Animal Trial.Obesity surgery · 2019Article
- Small Bowel Endoscopic Bariatric Therapies.Clinical endoscopy · 2018Article
- The EndoBarrier: Duodenal-Jejunal Bypass Liner for Diabetes and Weight Loss.Gastroenterology research and practice · 2018Review
- Endoscopic Treatments for Obesity.Current treatment options in gastroenterology · 2017Review
- Procedures and devices for bariatric and metabolic endoscopy.Therapeutic advances in gastrointestinal endoscopyReview
- Overview of bariatric and metabolic endoscopy interventions.Therapeutic advances in gastrointestinal endoscopyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe duodenal-jejunal bypass liner (DJBL) is an endoscopic device that mimics the duodenal-jejunal exclusion component of the Roux-en-Y gastric bypass. Previous studies assessing the efficacy of the DJBL have shown 10-40% excess weight loss (%EWL) and improvements in obesity-associated comorbidities. The aim of this study was to evaluate the safety and efficacy of a new DJBL prototype over a 3-year period.
methodsMorbidly obese subjects were enrolled in a single-arm, open-label, prospective trial. The subjects were offered the opportunity to continue with the trial annually and signed a new consent form. The primary endpoint was safety. The secondary endpoints were changes in weight and biochemical parameters from baseline.
resultsThe DJBL was implanted endoscopically in 80 subjects (age: 35±10 years; 69% female; weight: 109±17 kg; BMI: 42±5.4 kg/m
conclusionThis study shows significant and sustained weight loss after 3 years of treatment with the new DJBL. However, the high frequency and severity of AEs preclude the use of this prototype for periods longer than 1 year.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.